Ascendis Pharma files Form 144 to sell 10,800 shares

Ascendis Pharma A/S reported a proposed sale of 10,800 ordinary shares via Citigroup Global Markets on 03/02/2026.

Rhea-AI Filing Summary

Ascendis Pharma A/S reported a proposed sale of 10,800 ordinary shares via Citigroup Global Markets on 03/02/2026. The filing also shows 18,349 restricted shares vesting on 03/02/2026 as compensation, and discloses 10,000 shares sold on 12/02/2025 for $2,058,454.18.

Insights

Corporate Governance Analyst

Form 144 notifies a brokered sale and discloses recent insider dispositions and vesting.

The filing lists a proposed sale of 10,800 ordinary shares through Citigroup Global Markets on 03/02/2026. It separately records 18,349 restricted shares vesting on that date as compensation.

Reported prior activity shows a disposition of 10,000 shares on 12/02/2025 for $2,058,454.18. Timing and cash‑flow treatment for the proposed sale are those typical of brokered transactions; specific proceeds recipients are not stated in the excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Ascendis Pharma's (ASND) Form 144 disclose?

The Form 144 discloses a proposed sale of 10,800 ordinary shares through Citigroup on 03/02/2026. It also lists 18,349 restricted shares vesting on that date and a prior sale of 10,000 shares on 12/02/2025.

How many restricted shares are vesting for ASND and when?

18,349 restricted shares are shown as vesting on 03/02/2026 and are labeled as compensation in the filing. The entry identifies the grant type and the vesting date explicitly.

Who is the broker handling the proposed ASND sale?

The filing names Citigroup Global Markets at 390 Greenwich St, New York, as the broker for the proposed transaction scheduled on 03/02/2026. The broker is listed in the securities-to-be-sold section.

What recent insider sales does the Form 144 show for ASND?

The document reports a prior sale of 10,000 ordinary shares on 12/02/2025 with proceeds of $2,058,454.18. That sale is listed under securities sold during the past three months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 04:23 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001965612
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Ascendis Pharma A/S
SEC File Number	001-36815
Address of Issuer	TUBORG BOULEVARD 12 HELLERUP NETHERLANDS 1105 BP
Phone	45 70 22 22 44
Name of Person for Whose Account the Securities are To Be Sold	JENSEN FLEMMING STEEN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	EXECUTIVE VP HEAD OF PRODUCT SUPPLY AND QUALITY

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	10800	2614572.00	61977408	03/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/02/2026	RESTRICTED STOCK VESTING	ASCENDIS PHARMA A/S			18349	03/02/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JENSEN FLEMMING STEEN TUBORG BOULEVARD 12 HELLERUP G7 DK2900	ORDINARY SHARES	12/02/2025	10000	2058454.18

144: Remarks and Signature

Remarks	UNDER SECTION 3D INDICATIVE MARKET PRICE IS 242.09. SHARES BEING SOLD FOR THE VESTING AND SETTLEMENT OF EQUITY AWARDS. UNDER SECURITIES TO BE SOLD DATE ACQUIRED ARE VARIOUS DATES.THE INTENDED NUMBER OF SHARES IS AN APPRROXIMATION DUE TO MARKET CONDITIONS. THE SALES WILL TAKE PLACE OVER MULTIPLE DAYS. THESE ARE NON DISCRETIONARY TRANSACTIONS. THESE ARE BEING PERFORMED UNDER AN ESTABLISHED 10B51 PLAN
Date of Notice	03/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/07/2023
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)